Clinical trial
A Prospective Study on the Effect of Minimal Residual Disease Detected by Fibroblast Activation Protein PET / CT on the Recurrence of IgG4-related Disease
NCT07104058 is registered in ClinicalTrials.gov with Luo Yaping as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective Study on the Effect of Minimal Residual Disease Detected by Fibroblast Activation Protein PET / CT on the Recurrence of IgG4-related Disease
- Lead sponsor
- Luo Yaping
- Phase
- Not applicable
- Overall status
- Recruiting
- Start date
- May 10, 2025
- Completion date
- December 1, 2027
- Enrollment
- 46 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
igg4-related diseases